Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Excision BioTherapeutics has raised $6.8M in total funding. The most recent round was Grant. The last funding was announced in September 2022.
Excision BioTherapeutics's investors include Norwest, Alumni Ventures, ARCH Venture Partners, Abstract, Gaingels.
Excision BioTherapeutics is headquartered in Philadelphia, United States.
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Excision BioTherapeutics is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Excision BioTherapeutics — Funding & Investors." VCBacked, September 29, 2022, https://www.vcbacked.co/company/excision-biotherapeutics. Accessed July 20, 2026.
VCBacked. (2022). Excision BioTherapeutics — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/excision-biotherapeutics
{{cite web |title=Excision BioTherapeutics — Funding & Investors |url=https://www.vcbacked.co/company/excision-biotherapeutics |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated